Squarepoint
FBRX

Squarepoint’s Forte Biosciences FBRX Stock Holding History

Squarepoint’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$262K Sell
12,317
-8,438
-41% -$200K ﹤0.01% 3911
2026
Q1 		$538K Buy
+20,755
New +$598K ﹤0.01% 3282
2022
Q1 		– Sell
-525
Closed -$28K – 3052
2021
Q4 		$28K Buy
+525
New +$35.3K ﹤0.01% 3074
2021
Q2 		– Sell
-463
Closed -$397K – 3370
2021
Q1 		$397K Buy
+463
New +$379K ﹤0.01% 2197
2019
Q2 		– Sell
-34
Closed -$140K – 2461
2019
Q1 		$140K Sell
34
-62
-65% -$240K ﹤0.01% 2001
2018
Q4 		$295K Buy
+96
New +$413K ﹤0.01% 1519

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Squarepoint's FBRX Position: Q2 2026 in Review

Squarepoint reduced its Forte Biosciences (FBRX) stake by 41% in Q2 2026, selling an estimated $200K and leaving 12,317 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #3911.

Squarepoint first reported a position in FBRX in Q4 2018 and has held it in 6 quarters since. The position peaked at $538K in Q1 2026. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Squarepoint held 12,317 shares of Forte Biosciences worth $262K as of Q2 2026.
  • Squarepoint sold 8,438 Forte Biosciences shares in Q2 2026, an estimated $200K.
  • Forte Biosciences made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3911 holding.
  • Squarepoint first reported a position in Forte Biosciences in Q4 2018 and has held it in 6 quarters since.
  • Squarepoint's Forte Biosciences position peaked at $538K in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.